What is Flare Therapeutics?
Flare Therapeutics operates at the intersection of chemical biology and proteomics, focusing on the development of precision medicines. The company's core mission is to unlock the therapeutic potential of transcription factors, which have historically been considered challenging targets in drug discovery. Through its specialized platform, the firm is advancing a robust pipeline of small-molecule therapies, with a primary emphasis on oncology and cancer treatment. By integrating advanced proteomics with sophisticated drug discovery techniques, Flare Therapeutics is effectively bridging the gap between complex biological insights and actionable clinical outcomes, establishing a formidable presence in the biotechnology sector.
How much funding has Flare Therapeutics raised?
Flare Therapeutics has raised a total of $290M across 3 funding rounds:
Series A
$82M
Series B
$123M
Series C
$85M
Series A (2021): $82M with participation from Eventide Asset Management, Invus Financial Advisors, Casdin Capital, Boxer Capital, Third Rock Ventures, and Nextech Invest
Series B (2023): $123M led by Pavilion Capital, Eventide Asset Management, Boxer Capital, GordonMD Global Investments, ShangBay Capital, Pfizer Ventures, and Casdin Capital
Series C (2026): $85M supported by Pfizer, Novartis, Lilly, Boxer Capital, GordonMD Global Investments, Third Rock Ventures, Agent Capital, Eventide Asset Management, Nextech Invest, and Casdin Capital
Key Investors in Flare Therapeutics
Pfizer
A global biopharmaceutical leader that researches, develops, and manufactures innovative medicines and vaccines, with a strong strategic focus on oncology and immunology.
Novartis
A Swiss-based global pharmaceutical manufacturer dedicated to developing innovative healthcare solutions and treatments across multiple therapeutic areas to improve patient outcomes.
Lilly
A global biopharmaceutical firm focused on the discovery and commercialization of prescription medicines in areas including oncology, neuroscience, and immunology.
What's next for Flare Therapeutics?
With the infusion of this latest capital, Flare Therapeutics is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company's strategic roadmap focuses on validating its lead candidates in human trials while further refining its proprietary drug discovery engine. As the firm transitions into more advanced stages of development, the continued support from major pharmaceutical partners and venture capital firms provides the necessary operational runway to navigate the complexities of the oncology market. Future growth will likely center on expanding the therapeutic reach of its transcription factor-targeting platform, potentially addressing a broader range of indications beyond current oncology targets.
See full Flare Therapeutics company page
